Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Pharmacol Exp Ther ; 356(2): 434-44, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26582732

ABSTRACT

Parkinson's disease is frequently associated with gastrointestinal symptoms, mostly represented by constipation and defecatory dysfunctions. This study examined the impact of central dopaminergic denervation, induced by injection of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle, on distal colonic excitatory cholinergic neuromotor activity in rats. Animals were euthanized 4 and 8 weeks after 6-OHDA injection. In vivo colonic transit was evaluated by radiologic assay. Electrically induced and carbachol-induced cholinergic contractions were recorded in vitro from longitudinal and circular muscle colonic preparations, whereas acetylcholine levels were assayed in the incubation media. Choline acetyltransferase (ChAT), HuC/D (pan-neuronal marker), muscarinic M2 and M3 receptors were assessed by immunohistochemistry or western blot assay. As compared with control rats, at week 4, 6-OHDA-treated animals displayed the following changes: decreased in vivo colonic transit rate, impaired electrically evoked neurogenic cholinergic contractions, enhanced carbachol-induced contractions, decreased basal and electrically stimulated acetylcholine release from colonic tissues, decreased ChAT immunopositivity in the neuromuscular layer, unchanged density of HuC/D immunoreactive myenteric neurons, and increased expression of colonic muscarinic M2 and M3 receptors. The majority of such alterations were also detected at week 8 post 6-OHDA injection. These findings indicate that central nigrostriatal dopaminergic denervation is associated with an impaired excitatory neurotransmission characterized by a loss of myenteric neuronal ChAT positivity and decrease in acetylcholine release, resulting in a dysregulated smooth muscle motor activity, which likely contributes to the concomitant decrease in colonic transit rate.


Subject(s)
Acetylcholine/metabolism , Colon/diagnostic imaging , Colon/metabolism , Enteric Nervous System/diagnostic imaging , Enteric Nervous System/metabolism , Gastrointestinal Motility/physiology , Parkinsonian Disorders/diagnostic imaging , Animals , Cholinergic Neurons/diagnostic imaging , Cholinergic Neurons/metabolism , Male , Organ Culture Techniques , Radiography , Rats , Rats, Sprague-Dawley , Synaptic Transmission/physiology
2.
J Nucl Med ; 55(3): 396-404, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24481024

ABSTRACT

UNLABELLED: (-)-5-(18)F-fluoroethoxybenzovesamicol ((18)F-FEOBV) is a vesamicol derivative that binds selectively to the vesicular acetylcholine transporter (VAChT) and has been used in preclinical studies to quantify presynaptic cholinergic nerve terminals. This study presents, to our knowledge, the first-in-human experience with (18)F-FEOBV, including radiation dosimetry, biodistribution, tolerability and safety in human subjects, and brain kinetics and methods for quantitative analysis of (18)F-FEOBV. METHODS: Whole-body (18)F-FEOBV scans were obtained in 3 healthy human volunteers. Seven additional subjects underwent dynamic brain imaging 0-120, 150-180, and 210-240 min after bolus injection of (18)F-FEOBV. Arterial blood sampling was performed with chromatographic identification of authentic (18)F-FEOBV to determine the arterial plasma input function. Analysis methods included nonlinear least-squares fitting of a 2-tissue-compartmental model, reference tissue modeling, and late single-scan imaging. RESULTS: No pharmacologic or physiologic changes were observed after intravenous administration of up to 1.3 µg of (18)F-FEOBV. Radiation dosimetry estimates indicate that more than 400 MBq may be administered without exceeding regulatory radiation dose limits. Kinetic analysis showed brain uptake to be relatively high with single-pass extraction of 25%-35%. VAChT binding estimates varied by a factor of greater than 30 between the striatum and cortex. Coefficients of variation in k3 estimates varied from 15% to 30%. Volume of distribution measures yielded a dynamic range of approximately 15 but with little reduction in variability. Reference tissue approaches yielded more stable estimates of the distribution volume ratio (1 + BPND), with coefficients of variation ranging from 20% in the striatum to 6%-12% in cortical regions. The late static distribution of (18)F-FEOBV correlated highly with the distribution volume ratio estimates from reference tissue models (r = 0.993). CONCLUSION: (18)F-FEOBV PET confirms that the tracer binds to VAChT with the expected in vivo human brain distribution. Both reference tissue modeling and late static scanning approaches provide a robust index of VAChT binding.


Subject(s)
Cholinergic Neurons/cytology , Cholinergic Neurons/diagnostic imaging , Piperidines/pharmacokinetics , Positron-Emission Tomography/methods , Adolescent , Adult , Aged , Brain/cytology , Brain/diagnostic imaging , Brain/metabolism , Cholinergic Neurons/metabolism , Female , Humans , Kinetics , Male , Middle Aged , Piperidines/adverse effects , Radioactive Tracers , Radiometry , Safety , Tissue Distribution , Vesicular Acetylcholine Transport Proteins/metabolism , Young Adult
3.
Nucl Med Biol ; 41(1): 96-101, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24267056

ABSTRACT

INTRODUCTION: [(18)F]fluoroethoxybenzovesamicol ([(18)F]FEOBV) is a PET radiotracer with high selectivity and specificity to the vesicular acetylcholine transporter (VAChT). It has been shown to be a sensitive in vivo measurement of changes of cholinergic innervation densities following lesion of the nucleus basalis of Meynert (NBM) in rat. The current study used [(18)F]FEOBV with PET imaging to detect the effect of a highly selective lesion of the pedunculopontine (PPTg) nucleus in rat. METHODS: After bilateral and selective lesions of the PPTg cholinergic neurons, rats were scanned using [(18)F]FEOBV, then sacrificed, and their brain tissues collected for immunostaining and quantification of the VAChT. RESULTS: Comparisons with control rats revealed that cholinergic losses can be detected in the brainstem, lateral thalamus, and pallidum by using both in vivo imaging methods with [(18)F]FEOBV, and ex vivo measurements. In the brainstem PPTg area, significant correlations were observed between in vivo and ex vivo measurements, while this was not the case in the thalamic and pallidal projection sites. CONCLUSIONS: These findings support PET imaging with [(18)F]FEOBV as a reliable in vivo method for the detection of neuronal terminal losses resulting from lesion of the PPTg. Useful applications can be found in the study of neurodegenerative diseases in human, such as Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or dementia with Lewy bodies.


Subject(s)
Cholinergic Neurons/diagnostic imaging , Pedunculopontine Tegmental Nucleus/cytology , Piperidines , Positron-Emission Tomography , Animals , Male , Rats
4.
Neurobiol Aging ; 35(3): 482-91, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24176625

ABSTRACT

We compared accuracy of hippocampus and basal forebrain cholinergic system (BFCS) atrophy to predict cortical amyloid burden in 179 cognitively normal subjects (CN), 269 subjects with early stages of mild cognitive impairment (MCI), 136 subjects with late stages of MCI, and 86 subjects with Alzheimer's disease (AD) dementia retrieved from the Alzheimer's Disease Neuroimaging Initiative database. Hippocampus and BFCS volumes were determined from structural magnetic resonance imaging scans at 3 Tesla, and cortical amyloid load from AV45 (florbetapir) positron emission tomography scans. In receiver operating characteristics analyses, BFCS volume provided significantly more accurate classification into amyloid-negative and -positive categories than hippocampus volume. In contrast, hippocampus volume more accurately identified the diagnostic categories of AD, late and early MCI, and CN compared with whole and anterior BFCS volume, whereas posterior BFCS and hippocampus volumes yielded similar diagnostic accuracy. In logistic regression analysis, hippocampus and posterior BFCS volumes contributed significantly to discriminate MCI and AD from CN, but only BFCS volume predicted amyloid status. Our findings suggest that BFCS atrophy is more closely associated with cortical amyloid burden than hippocampus atrophy in predementia AD.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Cerebral Cortex/metabolism , Cholinergic Neurons/pathology , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/pathology , Prosencephalon/pathology , Aged , Aged, 80 and over , Atrophy , Cholinergic Neurons/diagnostic imaging , Female , Hippocampus/diagnostic imaging , Hippocampus/pathology , Humans , Magnetic Resonance Imaging , Male , Positron-Emission Tomography , Prosencephalon/cytology , Prosencephalon/diagnostic imaging
5.
Parkinsonism Relat Disord ; 20(1): 13-6, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24070538

ABSTRACT

BACKGROUND: It is unknown whether driving difficulty in Parkinson disease (PD) is attributable to nigrostriatal dopaminergic or extranigral non-dopaminergic neurodegeneration. OBJECTIVE: To investigate in vivo imaging differences in dopaminergic and cholinergic innervation between PD patients with and without a history of risky driving. METHODS: Thirty non-demented PD subjects (10 women/20 men) completed a driving survey. These subjects had previously undergone (+)-[(11)C] dihydrotetrabenazine vesicular monoamine transporter 2 and [(11)C] methyl-4-piperidinyl propionate acetylcholinesterase PET imaging. Acetylcholinesterase PET imaging assesses cholinergic terminal integrity with cortical uptake largely reflecting basal forebrain and thalamic uptake principally reflecting pedunculopontine nucleus integrity. RESULTS: Eight of thirty subjects reported a history of risky driving (been pulled over, had a traffic citation, or been in an accident since PD onset) while 22 had no such history (safe drivers). There was no difference in striatal dihydrotetrabenazine vesicular monoamine transporter uptake between risky and safe drivers. There was significantly less thalamic acetylcholinesterase activity in the risky drivers compared to safe drivers (0.0513 ± 0.006 vs. 0.0570 ± 0.006, p = 0.022) but no difference in neocortical acetylcholinesterase activity. Using multivariable logistic regression, decreased thalamic acetylcholinesterase activity remained an independent predictor of risky driving in PD even after controlling for age and disease duration. CONCLUSIONS: Risky driving is related to pedunculopontine nucleus-thalamic but not neocortical cholinergic denervation or nigrostriatal dopaminergic denervation in PD. This suggests that degeneration of the pedunculopontine nucleus, a brainstem center responsible for postural and gait control, plays a role in the ability of PD patients to drive.


Subject(s)
Automobile Driving , Nerve Degeneration/diagnostic imaging , Parkinson Disease/complications , Parkinson Disease/diagnostic imaging , Cholinergic Neurons/diagnostic imaging , Cholinergic Neurons/pathology , Female , Humans , Male , Nerve Degeneration/pathology , Parkinson Disease/pathology , Pedunculopontine Tegmental Nucleus/diagnostic imaging , Pedunculopontine Tegmental Nucleus/pathology , Positron-Emission Tomography , Thalamus/diagnostic imaging , Thalamus/pathology
6.
Brain ; 136(Pt 11): 3282-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24056537

ABSTRACT

The pathophysiology of postural instability in Parkinson's disease remains poorly understood. Normal postural function depends in part on the ability of the postural control system to integrate visual, proprioceptive, and vestibular sensory information. Degeneration of cholinergic neurons in the brainstem pedunculopontine nucleus complex and their thalamic efferent terminals has been implicated in postural control deficits in Parkinson's disease. Our aim was to investigate the relationship of cholinergic terminal loss in thalamus and cortex, and nigrostriatal dopaminergic denervation, on postural sensory integration function in Parkinson's disease. We studied 124 subjects with Parkinson's disease (32 female/92 male; 65.5 ± 7.4 years old; 6.0 ± 4.2 years motor disease duration; modified Hoehn and Yahr mean stage 2.4 ± 0.5) and 25 control subjects (10 female/15 male, 66.8 ± 10.1 years old). All subjects underwent (11)C-dihydrotetrabenazine vesicular monoaminergic transporter type 2 and (11)C-methylpiperidin-4-yl propionate acetylcholinesterase positron emission tomography and the sensory organization test balance platform protocol. Measures of dopaminergic and cholinergic terminal integrity were obtained, i.e. striatal vesicular monoaminergic transporter type 2 binding (distribution volume ratio) and thalamic and cortical acetylcholinesterase hydrolysis rate per minute (k3), respectively. Total centre of pressure excursion (speed), a measure of total sway, and sway variability were determined for individual sensory organization test conditions. Based on normative data, principal component analysis was performed to reduce postural sensory organization functions to robust factors for regression analysis with the dopaminergic and cholinergic terminal data. Factor analysis demonstrated two factors with eigenvalues >2 that explained 52.2% of the variance, mainly reflecting postural sway during sensory organization test Conditions 1-3 and 5, respectively. Regression analysis of the Conditions 1-3 postural sway-related factor [R(2)adj = 0.123, F(5,109) = 4.2, P = 0.002] showed that decreased thalamic cholinergic innervation was associated with increased centre of pressure sway speed (ß = -0.389, t = -3.4, P = 0.001) while controlling for covariate effects of cognitive capacity and parkinsonian motor impairments. There was no significant effect of cortical cholinergic terminal deficits or striatal dopaminergic terminal deficits. This effect could only be found for the subjects with Parkinson's disease. We conclude that postural sensory integration function of subjects with Parkinson's disease is modulated by pedunculopontine nucleus-thalamic but not cortical cholinergic innervation. Impaired integrity of pedunculopontine nucleus cholinergic neurons and their thalamic efferents play a role in postural control in patients with Parkinson's disease, possibly by participating in integration of multimodal sensory input information.


Subject(s)
Cholinergic Neurons/metabolism , Parkinson Disease/physiopathology , Pedunculopontine Tegmental Nucleus/physiopathology , Positron-Emission Tomography/methods , Postural Balance/physiology , Thalamus/physiopathology , Aged , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Cholinergic Neurons/diagnostic imaging , Cross-Sectional Studies , Dopaminergic Neurons/diagnostic imaging , Dopaminergic Neurons/metabolism , Female , Humans , Male , Middle Aged , Neostriatum/diagnostic imaging , Neostriatum/metabolism , Neostriatum/physiopathology , Parkinson Disease/diagnostic imaging , Parkinson Disease/metabolism , Pedunculopontine Tegmental Nucleus/diagnostic imaging , Pedunculopontine Tegmental Nucleus/metabolism , Positron-Emission Tomography/instrumentation , Severity of Illness Index , Substantia Nigra/diagnostic imaging , Substantia Nigra/metabolism , Substantia Nigra/physiopathology , Thalamus/diagnostic imaging , Thalamus/metabolism
7.
J Neural Transm (Vienna) ; 120(10): 1421-4, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23532360

ABSTRACT

As Parkinson disease (PD) may affect men and women differentially, we investigated gender differences in regional projection system integrity in 148 PD subjects (36 women, 112 men) using monoaminergic [11C]dihydrotetrabenazine and acetylcholinesterase [11C]PMP positron emission tomography. After controlling for age, disease duration, and Hoehn and Yahr score, men showed 5.9% greater caudate dopaminergic denervation (p = 0.0018) and 5.8% greater neocortical cholinergic denervation (p = 0.0097). No significant gender differences were seen in putaminal dopaminergic or thalamic cholinergic denervation.


Subject(s)
Brain/diagnostic imaging , Cholinergic Neurons/diagnostic imaging , Dopaminergic Neurons/diagnostic imaging , Parkinson Disease/diagnostic imaging , Sex Characteristics , Cross-Sectional Studies , Female , Humans , Male , Positron-Emission Tomography
8.
Ann Neurol ; 71(4): 560-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22522445

ABSTRACT

OBJECTIVE: Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. RBD and cholinergic system degeneration are identified independently as risk factors for cognitive impairment in PD. We aimed to assess the association between cholinergic denervation and symptoms of RBD in PD patients without dementia. METHODS: Eighty subjects with PD without dementia (age, 64.6 ± 7.0 years; range, 50-82 years; 60 males, 20 females; mean Montreal Cognitive Assessment Test [MoCA] score, 26.2 ± 2.1; range 21-30) underwent clinical assessment, neuropsychological testing, and [(11)C]methylpiperidyl propionate acetylcholinesterase and [(11)C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission tomography (PET) imaging. (11)C3-Amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile (DASB) serotonin transporter PET imaging was performed in a subset of 35 subjects. The presence of RBD symptoms was determined using the Mayo Sleep Questionnaire. RESULTS: Twenty-seven of 80 subjects (33.8%) indicated a history of RBD symptoms. Subjects with and without RBD symptoms showed no significant differences in age, motor disease duration, MoCA, Unified Parkinson Disease Rating Scale motor scores, or striatal DTBZ binding. Subjects with RBD symptoms, in comparison to those without, exhibited decreased neocortical, limbic cortical, and thalamic cholinergic innervation (0.0213 ± 0.0018 vs 0.0236 ± 0.0022, t = 4.55, p < 0.0001; 0.0388 ± 0.0029 vs 0.0423 ± 0.0058, t = 2.85, p = 0.0056; 0.0388 ± 0.0025 vs 0.0427 ± 0.0042, t = 4.49, p < 0.0001, respectively). Brainstem and striatal DASB binding showed no significant differences between groups. INTERPRETATION: The presence of RBD symptoms in PD is associated with relative neocortical, limbic cortical, and thalamic cholinergic denervation although not with differential serotoninergic or nigrostriatal dopaminergic denervation. The presence of RBD symptoms may signal cholinergic system degeneration.


Subject(s)
Cholinergic Neurons/diagnostic imaging , Parkinson Disease/diagnostic imaging , REM Sleep Behavior Disorder/diagnostic imaging , Acetylcholine/analysis , Acetylcholine/metabolism , Aged , Cholinergic Agents , Cholinergic Neurons/metabolism , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Parkinson Disease/complications , Parkinson Disease/metabolism , Positron-Emission Tomography , REM Sleep Behavior Disorder/etiology , REM Sleep Behavior Disorder/metabolism , Radiopharmaceuticals , Serotonin Plasma Membrane Transport Proteins/analysis , Serotonin Plasma Membrane Transport Proteins/metabolism , Vesicular Monoamine Transport Proteins/analysis , Vesicular Monoamine Transport Proteins/metabolism
9.
Neurosci Lett ; 514(2): 169-72, 2012 Apr 18.
Article in English | MEDLINE | ID: mdl-22414859

ABSTRACT

There are two major sources of cholinergic projections in the brain. The nucleus basalis of Meynert provides the principal cholinergic input of the cortical mantle and the pedunculopontine nucleus-laterodorsal tegmental complex (PPN-LDTC; hereafter referred to as PPN) provides the major cholinergic input to the thalamus. Cortical cholinergic denervation has previously been shown to be part of Alzheimer and parkinsonian dementia but there is less information about subcortical thalamic cholinergic denervation. We investigated thalamic cholinergic afferent integrity by measuring PPN-Thalamic (PPN-Thal) acetylcholinesterase (AChE) activity via PET imaging in Alzheimer (AD), Parkinson disease without dementia (PD), Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB). AD (n=13; mean age 75.4 ± 5.5), PD (n=11; age 71.4 ± 6.4), PDD (n=6; age 70.8±4.7), DLB (n=6; age 68.0 ± 8.6) and normal controls (NC; n=14; age 69.0 ± 7.5) subjects underwent AChE [¹¹C]-methyl-4-piperidinyl propionate (PMP) PET imaging. PPN-Thal PET data were analyzed using the Nagatsuka method. There were no significant differences in mean age between the groups (F=1.86, p=0.134). Kruskal-Wallis testing demonstrated a significant group effect for PPN-Thal AChE hydrolysis rates (F=9.62, p<0.0001). Compared to NC, reduced thalamic k3 hydrolysis rate was noted in subjects with PDD (-19.8%; AChE k3 hydrolysis rates 0.1072 ± 0.0143 min⁻¹), DLB (-17.4%; 0.1103 ± 0.0112 min⁻¹) and PD (-12.8%; 0.1165 ± 0.0114 min⁻¹). Each of these 3 subgroups was statistically different from AD subjects (-0.7%; 0.1326 ± 0.0095 min⁻¹) who showed relatively spared thalamic k3 hydrolysis rates which were comparable to NC (0.1336 ± 0.0142 min⁻¹). Thalamic cholinergic denervation is present in PD, PDD, and DLB but not in AD. Neurodegenerative involvement of thalamic cholinergic afferent projections may contribute to disease-specific motor and cognitive abnormalities.


Subject(s)
Alzheimer Disease/metabolism , Cholinergic Neurons/metabolism , Parkinsonian Disorders/metabolism , Thalamus/metabolism , Acetylcholinesterase/metabolism , Aged , Aged, 80 and over , Alzheimer Disease/diagnostic imaging , Cholinergic Neurons/diagnostic imaging , Female , Humans , Male , Middle Aged , Neural Pathways/diagnostic imaging , Neural Pathways/metabolism , Neuropsychological Tests , Parkinsonian Disorders/diagnostic imaging , Pedunculopontine Tegmental Nucleus/diagnostic imaging , Pedunculopontine Tegmental Nucleus/metabolism , Radionuclide Imaging , Thalamus/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...